Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand.

IF 6.6 2区 医学 Q1 RESPIRATORY SYSTEM
Respirology Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI:10.1111/resp.14865
Allie Eathorne, Jonathan Noble, Lee Hatter, Tom Hills, Selwyn Te Paa, Matire Harwood, Mark Weatherall, Richard Beasley
{"title":"Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand.","authors":"Allie Eathorne, Jonathan Noble, Lee Hatter, Tom Hills, Selwyn Te Paa, Matire Harwood, Mark Weatherall, Richard Beasley","doi":"10.1111/resp.14865","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>In Aotearoa New Zealand (NZ) widespread transition to budesonide/formoterol maintenance and/or reliever regimens in clinical practice is temporally associated with reduced rates of asthma hospitalization. It is unknown whether this association is observed in Māori, the indigenous population of NZ, who experience a disproportionate burden from asthma. We investigated patterns in asthma medication use and hospital admissions in Māori in NZ.</p><p><strong>Methods: </strong>Review of NZ national dispensing data for asthma inhaler medications and asthma hospital discharge data from January 2013 to December 2023 in the 12+ age group, with calculation of the relative change in dispensed medication and asthma hospitalization rates for Māori and non-Māori. The most recent six-month period, July to December 2023, is compared with the corresponding six-month period 4 years earlier, July to December 2019.</p><p><strong>Results: </strong>Budesonide/formoterol dispensing increased for both Māori and non-Māori for 2019-2023, with a relative 111% and 115% increase, respectively. Between the two periods, asthma hospital discharges reduced from 142.5 to 97.3 per 100,000, absolute difference 45.2 per 100,000, a 32% reduction for Māori; and 49.4-37.9 per 100,000, absolute difference 11.5 per 100,000; a 23% reduction for non-Māori.</p><p><strong>Conclusion: </strong>The temporal association between a marked increase in dispensing of budesonide/formoterol maintenance and/or reliever regimens and reduced asthma hospitalization was observed for Māori and non-Māori, with a greater reduction in asthma hospitalization for Māori. Despite this reduction in health inequities, asthma hospitalization rates are two and a half times greater for Māori compared to non-Māori.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"206-216"},"PeriodicalIF":6.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.14865","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: In Aotearoa New Zealand (NZ) widespread transition to budesonide/formoterol maintenance and/or reliever regimens in clinical practice is temporally associated with reduced rates of asthma hospitalization. It is unknown whether this association is observed in Māori, the indigenous population of NZ, who experience a disproportionate burden from asthma. We investigated patterns in asthma medication use and hospital admissions in Māori in NZ.

Methods: Review of NZ national dispensing data for asthma inhaler medications and asthma hospital discharge data from January 2013 to December 2023 in the 12+ age group, with calculation of the relative change in dispensed medication and asthma hospitalization rates for Māori and non-Māori. The most recent six-month period, July to December 2023, is compared with the corresponding six-month period 4 years earlier, July to December 2019.

Results: Budesonide/formoterol dispensing increased for both Māori and non-Māori for 2019-2023, with a relative 111% and 115% increase, respectively. Between the two periods, asthma hospital discharges reduced from 142.5 to 97.3 per 100,000, absolute difference 45.2 per 100,000, a 32% reduction for Māori; and 49.4-37.9 per 100,000, absolute difference 11.5 per 100,000; a 23% reduction for non-Māori.

Conclusion: The temporal association between a marked increase in dispensing of budesonide/formoterol maintenance and/or reliever regimens and reduced asthma hospitalization was observed for Māori and non-Māori, with a greater reduction in asthma hospitalization for Māori. Despite this reduction in health inequities, asthma hospitalization rates are two and a half times greater for Māori compared to non-Māori.

减少种族不平等:新西兰奥特罗阿Māori哮喘药物使用和出院模式。
背景和目的:在新西兰奥特罗阿(NZ),临床实践中广泛过渡到布地奈德/福莫特罗维持和/或缓解方案与哮喘住院率的降低暂时相关。目前尚不清楚这种关联是否在Māori中观察到,新西兰土著人口承受着不成比例的哮喘负担。我们调查了新西兰Māori哮喘药物使用和住院模式。方法:回顾2013年1月至2023年12月新西兰12+年龄组哮喘吸入器药物调剂数据和哮喘住院出院数据,计算Māori和non-Māori的调剂药物和哮喘住院率的相对变化。最近的六个月(2023年7月至12月)与四年前的六个月(2019年7月至12月)进行了比较。结果:2019-2023年,Māori和non-Māori的布地奈德/福莫特罗配药量均有所增加,相对增幅分别为111%和115%。在这两个时期,哮喘医院的出院率从每10万人142.5人降至97.3人,绝对差值为每10万人45.2人,Māori降低了32%;49.4-37.9 / 10万,绝对差11.5 / 10万;non-Māori减少23%。结论:在Māori和non-Māori中,布地奈德/福莫特罗维持和/或缓解方案配药的显著增加与哮喘住院率降低之间存在时间相关性,其中Māori的哮喘住院率降低幅度更大。尽管卫生不平等现象有所减少,但Māori的哮喘住院率是non-Māori的2.5倍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respirology
Respirology 医学-呼吸系统
CiteScore
10.60
自引率
5.80%
发文量
225
审稿时长
1 months
期刊介绍: Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery. The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences. Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信